BR9808863A - Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama - Google Patents

Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama

Info

Publication number
BR9808863A
BR9808863A BR9808863-7A BR9808863A BR9808863A BR 9808863 A BR9808863 A BR 9808863A BR 9808863 A BR9808863 A BR 9808863A BR 9808863 A BR9808863 A BR 9808863A
Authority
BR
Brazil
Prior art keywords
compositions
methods
peptide
breast cancer
antiestrogenic
Prior art date
Application number
BR9808863-7A
Other languages
English (en)
Inventor
Richard J Pietras
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9808863A publication Critical patent/BR9808863A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçõES ANTIESTROGêNICAS PEPTìDICAS E MéTODOS PARA TRATAR CâNCER DE MAMA" A presente invenção refere-se a métodos e composições que compreendem peptídios nativos, mutagenizados especificamente no sítio e sintéticos compreendendo uma porção do receptor de estrogênio humano, ou co-ativador de receptor de estrogênio, e composições de ácido nucléico que codificam estas composições de polipeptídios. São também descritos métodos para sintetizar derivados de peptídio de fosfotirosila e maloniltirosila e seu uso como composições antiestrogênicas no tratamento de cânceres de mama, a preparação de composições farmacêuticas, kits para diagnósticos e o desenvolvimento de ensaios relacionados para uso em terapias antitumor.
BR9808863-7A 1997-04-14 1998-04-14 Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama BR9808863A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4354597P 1997-04-14 1997-04-14
PCT/US1998/007711 WO1998046250A1 (en) 1997-04-14 1998-04-14 Peptide antiestrogen compositions and methods for treating breast cancer

Publications (1)

Publication Number Publication Date
BR9808863A true BR9808863A (pt) 2001-09-18

Family

ID=21927706

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9808863-7A BR9808863A (pt) 1997-04-14 1998-04-14 Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama

Country Status (5)

Country Link
US (1) US6306832B1 (pt)
EP (1) EP1005357A1 (pt)
BR (1) BR9808863A (pt)
CA (1) CA2286877A1 (pt)
WO (1) WO1998046250A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
AU762006B2 (en) * 1998-12-24 2003-06-19 Ucb Peptidic product, process and composition
WO2001068145A2 (en) 2000-03-15 2001-09-20 Bristol-Myers Squibb Pharma Company Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
US6818741B2 (en) * 2000-06-01 2004-11-16 Clf Medical Technology Acceleration Program, Inc. Alpha-fetoprotein peptides and uses therof
US7132400B2 (en) 2001-06-02 2006-11-07 Clf Medical Technology Acceleration Program, Inc. Alpha-fetoprotein peptides and uses thereof
AU2002363944A1 (en) * 2001-11-20 2003-06-10 Clf Medical Technology Acceleration Program, Inc. Alpha-fetoprotein peptides and uses for imaging
ATE540968T1 (de) 2001-11-20 2012-01-15 Albany Medical College Alpha-fetoproteinpeptide und deren verwendungen
US7943577B2 (en) * 2001-11-20 2011-05-17 Albany Medical College Alpha-fetoprotein peptides and uses thereof
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
CA2536946A1 (en) * 2003-08-26 2005-03-03 Board Of Regents, The University Of Texas System Estrogen receptor modulators and uses thereof
US20050255097A1 (en) * 2004-01-26 2005-11-17 Paul Reid Modified venom and venom components as anti-retroviral agents
US20060088843A1 (en) * 2004-10-25 2006-04-27 Reid Paul F Modified venom and venom components as anti-retroviral agents
US7964701B2 (en) 2006-02-24 2011-06-21 Albany Medical College Alpha-fetoprotein peptides
US7598342B2 (en) * 2006-02-24 2009-10-06 Albany Medical College Alpha-fetoprotein peptides and uses thereof
US20070225213A1 (en) * 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
US9517240B2 (en) 2006-09-26 2016-12-13 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
WO2008039482A2 (en) * 2006-09-26 2008-04-03 The Regents Of The University Of California Methods and compositions for cancer prevention and treatment
US20100189776A1 (en) 2007-03-16 2010-07-29 Cancer Research Technology Ltd Anti-androgen peptides and uses thereof in cancer therapy
US9249189B2 (en) 2010-01-18 2016-02-02 Albany Medical College Alpha-fetoprotein “ring and tail” peptides
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis
GB2513615A (en) 2013-05-01 2014-11-05 Cancer Rec Tech Ltd Medical use
US11110063B2 (en) 2017-08-25 2021-09-07 MAIA Pharmaceuticals, Inc. Storage stable sincalide formulations
US12129298B2 (en) 2018-06-21 2024-10-29 Daiichi Sankyo Company, Limited Compositions including CD3 antigen binding fragments and uses thereof
US20220177581A1 (en) 2019-03-11 2022-06-09 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4720455A (en) * 1985-09-06 1988-01-19 Pitman-Moore, Inc. Progesterone assay method for mammals and monoclonal antibody therefor
US5728534A (en) * 1996-07-19 1998-03-17 New England Medical Center Hospitals, Inc. Methods for identifying cardiovascular therapeutic agents

Also Published As

Publication number Publication date
EP1005357A1 (en) 2000-06-07
CA2286877A1 (en) 1998-10-22
AU7127398A (en) 1998-11-11
AU737627B2 (en) 2001-08-23
US6306832B1 (en) 2001-10-23
WO1998046250A1 (en) 1998-10-22

Similar Documents

Publication Publication Date Title
BR9808863A (pt) Composições antiestrogênicas peptìdicas e métodos para tratar câncer de mama
WO2001008636A8 (en) Polypeptides and polynucleotides for enhancing immune reactivity to her-2 protein
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
BR9808881A (pt) Compostos para imunoterapia de câncer de próstata e métodos para seu uso
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
BR9916207A (pt) Composições e métodos para terapia e diagnósticode câncer ovariano
ATE403001T1 (de) Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
BR9907259A (pt) Compostos para terapia e diagnóstico de câncer de pulmão e processos para o seu uso
BR0112542A (pt) Composições e métodos papa a terapia e a diagnose de câncer ovariano
NO913211L (no) Nytt monoklonalt antistoff mot nytt antigen knyttet til menneske-tumorer.
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
DE69933998D1 (de) Verbindungen und verfahren für therapie und diagnose von lungenkrebs
BR0210886A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
BR9808509A (pt) Composições e métodos para o tratamento e diagnóstico do câncer de mama
BR9508467A (pt) Composição de matéria peptídeo de ligação de receptor de somatostatina composição farmacéutica e processo para realizar uma cirurgia guiada por radiosótopos ou um procedimento de radiodiagnóstico ou radioterapéutico e para aliviar uma doença relacionada com somatostetina em um animal
WO2002088750A3 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
TR200103786T2 (tr) Güğüs kanserinin tehisi ve imünoterapisi için bileşikler ve bunların kullanımı
WO1999002545A3 (en) Antigen binding fragments, designated 4b5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO2001071357A3 (en) Diagnosis and treatment of breast cancer
BR0116763A (pt) Anticorpos humanos especìficos para terapia seletiva do c ncer
BRPI0407031A (pt) Composições e métodos para tratamento de câncer empregando igsf9 e liv-1
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1889 DE 20/03/2007.